A Phase I, Open Label, 2 Part Study to Determine the Pharmacokinetics of Olaparib 300 mg bd Administered as Monotherapy and Olaparib 100 mg bd as Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Olaparib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 09 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Feb 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 24 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 May 2017.